Table 2.

Number of participants contributing to each analysis

Trial	Number randomised			Time to withdrawal of allocated treatment			Time to 12‐month remission			Time to six‐month remission			Time to first seizure
	CBZ	PB	Total	CBZ	PB	Total	CBZ	PB	Total	CBZ	PB	Total	CBZ	PB	Total
Banu 2007¹	54	54	108	Information not available			Information not available			Information not available			54	54	108
de Silva 1996²	54	10	64	53	10	63	54	10	64	54	10	64	54	10	64
Heller 1995³	61	58	119	60	55	115	61	58	119	61	58	119	61	58	119
Mattson 1985⁴	155	155	310	154	155	309	154	155	309	154	155	309	151	151	302
Ogunrin 2005⁵	19	18	37	Information not available			Information not available			Information not available			19	18	37
Placencia 1993⁶	95	97	192	94	95	189	95	96	191	95	96	191	95	97	192
Total	438	392	830	361	315	676	364	319	683	364	319	683	434	388	822

CBZ: carbamazepine PB: phenobarbitone ¹The date of withdrawal of allocated treatment was not recorded in all cases for Banu 2007, so we could not calculate 'time to withdrawal of allocated treatment'. The date of first seizure after randomisation was recorded, but all dates of subsequent seizures were not recorded; therefore, we could calculate 'time to first seizure', but we could not calculate 'time to six‐month remission' and 'time to 12‐month remission'. ²We received IPD for 70 participants recruited in de Silva 1996; the randomised drug was not recorded in six participants. Reasons for treatment withdrawal were not available for one participant randomised to CBZ; we did not include this participant in the analysis of time to treatment withdrawal. ³Reasons for treatment withdrawal were not available for four participants (one randomised to CBZ and three to PB) in Heller 1995; we did not include these participants in the analysis of time to treatment withdrawal. ⁴No follow‐up data after randomisation were available for one participant randomised to CBZ in Mattson 1985. Dates of seizure recurrence were not available for seven participants (three randomised to CBZ and four to PB); we did not include these participants in the analysis of time to first seizure. ⁵The study duration of Ogunrin 2005 was 12 weeks; therefore, six‐ and 12‐month remission of seizures could not be achieved, so we could not calculate these outcomes. All randomised participants completed the study without withdrawing from treatment, so we could not analyse the time to treatment withdrawal. ⁶Reasons for treatment withdrawal were not available for three participants (one randomised to CBZ and two randomised to PB) in Placencia 1993. We did not include these participants in the analysis of time to treatment withdrawal. Seizure data after occurrence of first seizure were not available for one participant randomised to PB, so we did not include this participant in the analyses of time to six‐month and time to 12‐month remission.